A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis-Reference-Cited by-同舟云学术

A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis

Published:2020-07-05 Issue:8 Volume:9 Page:1003-1014
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Burmester Gerd¹,Chien David²,Chow Vincent³,Gessner Melissa⁴,Pan Jean²,Cohen Stanley⁵

Affiliation:

1. Department of Rheumatology and Clinical Immunology Charité – University Medicine Berlin Berlin Germany

2. Clinical R&D, Biosimilars Amgen Inc. Thousand Oaks California USA

3. Clinical Pharmacology M&S Amgen Inc. Thousand Oaks CA USA

4. Clinical Immunology Amgen Inc. Thousand Oaks CA USA

5. Metroplex Clinical Research Center Dallas Texas USA

Funder

Amgen

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.845

Reference18 articles.

1. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

2. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

3. B‐cell therapies for rheumatoid arthritis;Scher J;Bull NYU Hosp Jt Dis,2012

4. Rituximab: A Review in Pemphigus Vulgaris

5. Rituximab: Mechanism of Action

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis;Modern Rheumatology;2024-05-30

2. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25

3. Documento de consenso sobre los medicamentos biosimilares en enfermedades inmunomediadas en España;Reumatología Clínica;2023-10

4. Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain;Reumatología Clínica (English Edition);2023-10

5. Targeting of palpable B16-F10 melanoma tumors with polyclonal antibodies on white blood cells;Journal of Immunological Methods;2022-11